BTIG Research reaffirmed their hold rating on shares of Illumina (NASDAQ:ILMN) in a research note released on Tuesday.

ILMN has been the topic of a number of other research reports. Barclays upped their price target on shares of Illumina from $150.00 to $185.00 and gave the stock an equal weight rating in a research note on Wednesday, October 25th. Zacks Investment Research upgraded shares of Illumina from a hold rating to a buy rating and set a $229.00 price target on the stock in a research note on Friday, October 27th. Canaccord Genuity reiterated a buy rating and issued a $230.00 price target (up previously from $215.00) on shares of Illumina in a research note on Thursday, October 12th. Piper Jaffray Companies reiterated an overweight rating and issued a $226.00 price target (up previously from $202.00) on shares of Illumina in a research note on Monday, October 9th. Finally, Janney Montgomery Scott upgraded shares of Illumina from a sell rating to a neutral rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $220.13.

Illumina (NASDAQ ILMN) opened at $243.55 on Tuesday. The stock has a market cap of $35,560.00, a PE ratio of 45.95, a P/E/G ratio of 3.25 and a beta of 0.79. Illumina has a one year low of $156.50 and a one year high of $248.97. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. Illumina’s revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.97 EPS. analysts expect that Illumina will post 3.76 earnings per share for the current year.

In other news, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $210.43, for a total value of $4,208,600.00. Following the transaction, the director now owns 539,176 shares in the company, valued at approximately $113,458,805.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $243.72, for a total transaction of $3,655,800.00. Following the completion of the transaction, the director now owns 449,201 shares in the company, valued at approximately $109,479,267.72. The disclosure for this sale can be found here. Insiders have sold a total of 154,671 shares of company stock worth $33,626,228 in the last 90 days. Company insiders own 0.89% of the company’s stock.

Large investors have recently modified their holdings of the company. Dupont Capital Management Corp bought a new position in shares of Illumina in the 3rd quarter worth approximately $153,000. Advisory Services Network LLC lifted its stake in shares of Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares during the period. West Coast Financial LLC bought a new position in shares of Illumina in the 3rd quarter worth approximately $216,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Illumina in the 2nd quarter worth approximately $226,000. Finally, Colony Group LLC bought a new position in shares of Illumina in the 2nd quarter worth approximately $239,000. Hedge funds and other institutional investors own 91.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Illumina’s (ILMN) “Hold” Rating Reaffirmed at BTIG Research” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2018/01/20/illuminas-ilmn-hold-rating-reaffirmed-at-btig-research.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.